dispatches from technopharm

Personalised meds to deliver bigger market for oral film technologies says expert

By Dan Stanton

- Last updated on GMT

Outside Technopharm venue in Germany
Outside Technopharm venue in Germany

Related tags Printing

Flexible inkjet printing and personalized medicine will grow the market for orodispersible delivery technologies according to experts at a conference in Germany this week.

Orodispersible formulations comprise solid layer coated with APIs that are released when they dissolve in the oral cavity.

A number​ of such technologies​ are available, however, it is orodispersible films (ODF) that are set to capture a larger share of the market according to Jörg Breitkreutz, Chairman of the Germany-based scientific Association for Pharmaceutical Technology (APV).

He told attendees at TechnoPharm in Nuremberg, Germany, yesterday that “ODF will increasingly be an option for oral administration,”​ adding that while it will not replace tablet technology it is “definitely suited for the delivery of personalized medicines.”

Breitkreutz – who is also Director of the Institute of Pharmaceutical Technology and Biopharmacy at Dusseldorf University – explained that this is primarily due to technical innovations that now make it possible to “print” ​specific dosages.

Inkjet printing

“The first idea was to print the exact dose onto paper using a commercial inkjet printer,”​ he said, but developers found only about 0.05mg of the API was added by each pass and repeating the cycle would lead to abrasion and the loss of product.

However, he continued, German firm Tesa got around this problem for its product Setofilm - which treats chemotherapy and radiotherapy induced nausea - using a printing process known as flexography​, this is widely used in the newspaper industry.

Breitkreutz explained that the ability to use a flexible relief plate made the process much less abrasive and although it is “still limited to just six or seven print cycles, it is sufficient to add approximately 10mg of API to the film.”

Marketed products and oral lyophilisates

As well as Setofilm, there are a couple of other ODFs on the market but the first use of the technology was by Pfizer in 2001 in its consumer healthcare product Listerine.

However, Novartis’ Triaminic was the first drug approved in 2004, Breitkreutz said, but more regulatory updates and guidance for the dosage form is needed before this takes off.

Other rapidly dissolving drugs are currently on the market, with contract development and manufacturing firm Catalent using its Zydis sublingual oral dosage platform in over 20 approved products​, including Eli Lilly’s bipolar drug Zyprexa.

However, Zydis is an oral lyophilisate and suffers from the “fragile behavior of its materials,” ​Breitkreutz said, and this technology is evolving into orodispersible tablets, mini-tablets and ODF as drugmakers “search for cheaper methods of manufacture than the energy-intensive and costly lyophilisation process for freeze-dried platelets.”

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Related suppliers

Follow us


View more